サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1625428

オピオイド市場、規模、シェア、動向、産業分析レポート：クラス別、製品別、放出タイプ別、用途別、地域別 - 市場予測、2025年～2034年

Opioid Market Size, Share, Trends, Industry Analysis Report: By Class, Product, Release Type, Application, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 125 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
オピオイド市場、規模、シェア、動向、産業分析レポート：クラス別、製品別、放出タイプ別、用途別、地域別 - 市場予測、2025年～2034年
出版日: 2024年12月01日
発行: Polaris Market Research
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界のオピオイド市場規模は2034年までに284億5,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

オピオイド市場の成長は、企業間のパートナーシップの増加に起因しています。製薬会社、医療提供者、研究機関の提携により、オピオイド療法の新しい製剤や改良された送達システムの開発が促進されています。こうした提携により、企業はリソースを組み合わせ、専門知識を活用し、研究開発プロセスを迅速化することができるため、効果的な疼痛管理ソリューションをより早く市場に投入することが可能になります。さらに、戦略的提携は流通網を改善し、特に十分なサービスを受けていない地域におけるオピオイド治療薬へのアクセスを拡大します。安全性への懸念や法規制の遵守など、オピオイド処方に関連する課題に対処するために各社が手を組むことで、疼痛管理に対するより総合的なアプローチが促進され、最終的に市場におけるオピオイドの存在感が強まることになります。

外傷の有病率の増加は、効果的な疼痛管理の必要性から、オピオイド市場の需要を大きく牽引しています。米国では年間約150万件の外傷性脳損傷症例が報告されており、その多くが入院と長期疼痛管理を必要としています。CDCは、このようなケースの回復には疼痛管理が不可欠であり、オピオイドの需要を増大させると強調しています。さらに、外傷性脳損傷の長期的な影響に対する意識の高まりは、包括的な疼痛戦略の必要性を強調し、オピオイド処方のさらなる増加につながると予想されます。その結果、オピオイド市場規模は今後数年間で拡大する見通しです。

オピオイド市場は、疼痛管理に対する認識と教育の高まりによって拡大しています。患者もヘルスケアプロバイダーも、利用可能なさまざまな治療選択肢について理解を深めています。米国では、約5,000万人の成人が慢性疼痛に苦しんでいます。医療ガイドラインが更新されたことで、医師はオピオイドを処方する際に自信を持てるようになり、疼痛管理のためにオピオイドが適切に使用されるようになっています。このような疼痛治療の選択肢に対する理解の高まりが、慢性疼痛管理におけるオピオイド使用の増加に寄与しています。

オピオイド市場レポートハイライト

放出タイプ別では、放出延長型／長時間作用型オピオイドの分野が、予測期間中に世界市場で大幅なCAGRの成長を遂げると予測されています。この成長は、長時間作用型オピオイドを必要とする長時間の疼痛や外傷の有病率の増加に起因しています。

用途別では、慢性および急性の傷害の増加により、疼痛管理分野が2024年の市場で最大の収益シェアを占めました。

2024年には、北米がオピオイドの世界市場シェアを独占したが、これは病院数の増加により処方率が上昇しているためです。

インドのオピオイド市場は、資金調達と海外直接投資の流入の増加により、大幅な成長が予測されています。

世界の主要市場企業としては、 Aurobindo Pharma Limited; Assertio Therapeutics, Inc.; AbbVie Inc.; Actavis Plc.; Amneal Pharmaceuticals LLC; Boehringer Ingelheim International GmbH; Cadila Healthcare Limited; Fresenius Kabi; Mallinckrodt Pharmaceuticals; Endo International plc; Johnson & Johnson Corporation; Lupin Limited; Nesher Pharmaceuticals LLC; Purdue Pharma L.P.; Pfizer Inc.; Rhodes Pharmaceuticals L.P.; Sun Pharmaceutical Industries Limited; Trevena Inc.; Teva Pharmaceutical Industries Ltd.です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のオピオイド市場の洞察

  • 市場スナップショット
  • オピオイド市場力学
    • 促進要因と機会
      • 外傷性傷害の増加が市場規模の拡大を牽引
      • 医療インフラの拡張への投資増加が市場の成長を牽引
    • 抑制要因と課題
      • 厳格な政府規制
  • PESTEL分析
  • オピオイド市場の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界のオピオイド市場： クラス別

  • 主な調査結果
  • イントロダクション
  • 自然
  • 半合成
  • 完全合成

第6章 世界のオピオイド市場： 製品別

  • 主な調査結果
  • イントロダクション
  • コデイン
  • フェンタニル
  • オキシコドン
  • メサドン
  • モルヒネ
  • ヒドロコドン
  • トラマドール
  • プロポキシフェン
  • その他

第7章 世界のオピオイド市場： 放出タイプ別

  • 主な調査結果
  • イントロダクション
  • 即効性/短時間作用型オピオイド
  • 徐放性/長時間作用型オピオイド

第8章 世界のオピオイド市場： 用途別

  • 主な調査結果
  • イントロダクション
  • 疼痛管理
  • がんの痛み
  • 咳の治療
  • 鎮痛剤
  • 下痢の治療
  • 依存症からの脱却
  • その他

第9章 世界のオピオイド市場：地域別

  • 主な調査結果
  • イントロダクション
    • オピオイド市場の評価：地域、2020-2034年
  • 北米
    • 北米：クラス別、2020-2034年
    • 北米：製品別、2020-2034年
    • 北米：放出タイプ別、2020-2034年
    • 北米：用途別、2020-2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：クラス別、2020-2034年
    • 欧州：製品別、2020-2034年
    • 欧州：放出タイプ別、2020-2034年
    • 欧州：用途別、2020-2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：クラス別、2020-2034年
    • アジア太平洋地域：製品別、2020-2034年
    • アジア太平洋地域：放出タイプ別、2020-2034年
    • アジア太平洋地域：用途別、2020-2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：クラス別、2020-2034年
    • 中東・アフリカ：製品別、2020-2034年
    • 中東・アフリカ：放出タイプ別、2020-2034年
    • 中東・アフリカ：用途別、2020-2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：クラス別、2020-2034年
    • ラテンアメリカ：製品別、2020-2034年
    • ラテンアメリカ：放出タイプ別、2020-2034年
    • ラテンアメリカ：用途別、2020-2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第10章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第11章 企業プロファイル

  • Aurobindo Pharma Limited
  • Assertio Therapeutics, Inc.
  • AbbVie Inc.
  • Actavis Plc.
  • Amneal Pharmaceuticals LLC
  • Boehringer Ingelheim International GmbH
  • Cadila Healthcare Limited
  • Fresenius Kabi
  • Mallinckrodt Pharmaceuticals
  • Endo International plc
  • Johnson & Johnson Corporation
  • Lupin Limited
  • Nesher Pharmaceuticals LLC
  • Purdue Pharma L.P.
  • Pfizer Inc.
  • Rhodes Pharmaceuticals L.P.
  • Sun Pharmaceutical Industries Limited
  • Trevena Inc.
  • Teva Pharmaceutical Industries Ltd.
図表

List of Tables:

Table 1 Global Opioid Market, by Class, 2020-2034 (USD billion)

Table 2 Global Opioid Market, by Product, 2020-2034 (USD billion)

Table 3 Global Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 4 Global Opioid Market, by Application, 2020-2034 (USD billion)

Table 5 North America: Opioid Market, by Class, 2020-2034 (USD billion)

Table 6 North America: Opioid Market, by Product, 2020-2034 (USD billion)

Table 7 North America: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 8 North America: Opioid Market, by Application, 2020-2034 (USD billion)

Table 9 U.S.: Opioid Market, by Class, 2020-2034 (USD billion)

Table 10 U.S.: Opioid Market, by Product, 2020-2034 (USD billion)

Table 11 U.S.: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 12 U.S.: Opioid Market, by Application, 2020-2034 (USD billion)

Table 13 Canada: Opioid Market, by Class, 2020-2034 (USD billion)

Table 14 Canada: Opioid Market, by Product, 2020-2034 (USD billion)

Table 15 Canada: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 16 Canada: Opioid Market, by Application, 2020-2034 (USD billion)

Table 17 Europe: Opioid Market, by Class, 2020-2034 (USD billion)

Table 18 Europe: Opioid Market, by Product, 2020-2034 (USD billion)

Table 19 Europe: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 20 Europe: Opioid Market, by Application, 2020-2034 (USD billion)

Table 21 UK: Opioid Market, by Class, 2020-2034 (USD billion)

Table 22 UK: Opioid Market, by Product, 2020-2034 (USD billion)

Table 23 UK: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 24 UK: Opioid Market, by Application, 2020-2034 (USD billion)

Table 25 France: Opioid Market, by Class, 2020-2034 (USD billion)

Table 26 France: Opioid Market, by Product, 2020-2034 (USD billion)

Table 27 France: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 28 France: Opioid Market, by Application, 2020-2034 (USD billion)

Table 29 Germany: Opioid Market, by Class, 2020-2034 (USD billion)

Table 30 Germany: Opioid Market, by Product, 2020-2034 (USD billion)

Table 31 Germany: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 32 Germany: Opioid Market, by Application, 2020-2034 (USD billion)

Table 33 Italy: Opioid Market, by Class, 2020-2034 (USD billion)

Table 34 Italy: Opioid Market, by Product, 2020-2034 (USD billion)

Table 35 Italy: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 36 Italy: Opioid Market, by Application, 2020-2034 (USD billion)

Table 37 Spain: Opioid Market, by Class, 2020-2034 (USD billion)

Table 38 Spain: Opioid Market, by Product, 2020-2034 (USD billion)

Table 39 Spain: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 40 Spain: Opioid Market, by Application, 2020-2034 (USD billion)

Table 41 Netherlands: Opioid Market, by Class, 2020-2034 (USD billion)

Table 42 Netherlands: Opioid Market, by Product, 2020-2034 (USD billion)

Table 43 Netherlands: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 44 Netherlands: Opioid Market, by Application, 2020-2034 (USD billion)

Table 45 Russia: Opioid Market, by Class, 2020-2034 (USD billion)

Table 46 Russia: Opioid Market, by Product, 2020-2034 (USD billion)

Table 47 Russia: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 48 Russia: Opioid Market, by Application, 2020-2034 (USD billion)

Table 49 Rest of Europe: Opioid Market, by Class, 2020-2034 (USD billion)

Table 50 Rest of Europe: Opioid Market, by Product, 2020-2034 (USD billion)

Table 51 Rest of Europe: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 52 Rest of Europe: Opioid Market, by Application, 2020-2034 (USD billion)

Table 53 Asia Pacific: Opioid Market, by Class, 2020-2034 (USD billion)

Table 54 Asia Pacific: Opioid Market, by Product, 2020-2034 (USD billion)

Table 55 Asia Pacific: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 56 Asia Pacific: Opioid Market, by Application, 2020-2034 (USD billion)

Table 57 China: Opioid Market, by Class, 2020-2034 (USD billion)

Table 58 China: Opioid Market, by Product, 2020-2034 (USD billion)

Table 59 China: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 60 China: Opioid Market, by Application, 2020-2034 (USD billion)

Table 61 India: Opioid Market, by Class, 2020-2034 (USD billion)

Table 62 India: Opioid Market, by Product, 2020-2034 (USD billion)

Table 63 India: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 64 India: Opioid Market, by Application, 2020-2034 (USD billion)

Table 65 Malaysia: Opioid Market, by Class, 2020-2034 (USD billion)

Table 66 Malaysia: Opioid Market, by Product, 2020-2034 (USD billion)

Table 67 Malaysia: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 68 Malaysia: Opioid Market, by Application, 2020-2034 (USD billion)

Table 69 Japan: Opioid Market, by Class, 2020-2034 (USD billion)

Table 70 Japan: Opioid Market, by Product, 2020-2034 (USD billion)

Table 71 Japan: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 72 Japan: Opioid Market, by Application, 2020-2034 (USD billion)

Table 73 Indonesia: Opioid Market, by Class, 2020-2034 (USD billion)

Table 74 Indonesia: Opioid Market, by Product, 2020-2034 (USD billion)

Table 75 Indonesia: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 76 Indonesia: Opioid Market, by Application, 2020-2034 (USD billion)

Table 77 South Korea: Opioid Market, by Class, 2020-2034 (USD billion)

Table 78 South Korea: Opioid Market, by Product, 2020-2034 (USD billion)

Table 79 South Korea: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 80 South Korea: Opioid Market, by Application, 2020-2034 (USD billion)

Table 81 Australia: Opioid Market, by Class, 2020-2034 (USD billion)

Table 82 Australia: Opioid Market, by Product, 2020-2034 (USD billion)

Table 83 Australia: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 84 Australia: Opioid Market, by Application, 2020-2034 (USD billion)

Table 85 Rest of Asia Pacific: Opioid Market, by Class, 2020-2034 (USD billion)

Table 86 Rest of Asia Pacific: Opioid Market, by Product, 2020-2034 (USD billion)

Table 87 Rest of Asia Pacific: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 88 Rest of Asia Pacific: Opioid Market, by Application, 2020-2034 (USD billion)

Table 89 Middle East & Africa: Opioid Market, by Class, 2020-2034 (USD billion)

Table 90 Middle East & Africa: Opioid Market, by Product, 2020-2034 (USD billion)

Table 91 Middle East & Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 92 Middle East & Africa: Opioid Market, by Application, 2020-2034 (USD billion)

Table 93 Saudi Arabia: Opioid Market, by Class, 2020-2034 (USD billion)

Table 94 Saudi Arabia: Opioid Market, by Product, 2020-2034 (USD billion)

Table 95 Saudi Arabia: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 96 Saudi Arabia: Opioid Market, by Application, 2020-2034 (USD billion)

Table 97 UAE: Opioid Market, by Class, 2020-2034 (USD billion)

Table 98 UAE: Opioid Market, by Product, 2020-2034 (USD billion)

Table 99 UAE: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 100 UAE: Opioid Market, by Application, 2020-2034 (USD billion)

Table 101 Israel: Opioid Market, by Class, 2020-2034 (USD billion)

Table 102 Israel: Opioid Market, by Product, 2020-2034 (USD billion)

Table 103 Israel: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 104 Israel: Opioid Market, by Application, 2020-2034 (USD billion)

Table 105 South Africa: Opioid Market, by Class, 2020-2034 (USD billion)

Table 106 South Africa: Opioid Market, by Product, 2020-2034 (USD billion)

Table 107 South Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 108 South Africa: Opioid Market, by Application, 2020-2034 (USD billion)

Table 109 Rest of Middle East & Africa: Opioid Market, by Class, 2020-2034 (USD billion)

Table 110 Rest of Middle East & Africa: Opioid Market, by Product, 2020-2034 (USD billion)

Table 111 Rest of Middle East & Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 112 Rest of Middle East & Africa: Opioid Market, by Application, 2020-2034 (USD billion)

Table 113 Latin America: Opioid Market, by Class, 2020-2034 (USD billion)

Table 114 Latin America: Opioid Market, by Product, 2020-2034 (USD billion)

Table 115 Latin America: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 116 Latin America: Opioid Market, by Application, 2020-2034 (USD billion)

Table 117 Mexico: Opioid Market, by Class, 2020-2034 (USD billion)

Table 118 Mexico: Opioid Market, by Product, 2020-2034 (USD billion)

Table 119 Mexico: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 120 Mexico: Opioid Market, by Application, 2020-2034 (USD billion)

Table 121 Brazil: Opioid Market, by Class, 2020-2034 (USD billion)

Table 122 Brazil: Opioid Market, by Product, 2020-2034 (USD billion)

Table 123 Brazil: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 124 Brazil: Opioid Market, by Application, 2020-2034 (USD billion)

Table 125 Argentina: Opioid Market, by Class, 2020-2034 (USD billion)

Table 126 Argentina: Opioid Market, by Product, 2020-2034 (USD billion)

Table 127 Argentina: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 128 Argentina: Opioid Market, by Application, 2020-2034 (USD billion)

Table 129 Rest of Latin America: Opioid Market, by Class, 2020-2034 (USD billion)

Table 130 Rest of Latin America: Opioid Market, by Product, 2020-2034 (USD billion)

Table 131 Rest of Latin America: Opioid Market, by Release Type, 2020-2034 (USD billion)

Table 132 Rest of Latin America: Opioid Market, by Application, 2020-2034 (USD billion)

List of Figures:

Figure 1. Global Opioid Market, 2020-2034 (USD billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Class

Figure 7. Global Opioid Market, by Class, 2024 & 2034 (USD billion)

Figure 8. Market by Product

Figure 9. Global Opioid Market, by Product, 2024 & 2034 (USD billion)

Figure 10. Market by Release Type

Figure 11. Global Opioid Market, by Release Type, 2024 & 2034 (USD billion)

Figure 12. Market by Application

Figure 13. Global Opioid Market, by Application, 2024 & 2034 (USD billion)

Figure 14. Global Opioid Market Assessment, By Geography, 2020-2034 (USD billion)

  • Figure 15. Strategic Analysis - Global Opioid Market
目次
Product Code: PM1368

The global opioid market size is expected to reach USD 28.45 billion by 2034, according to a new study by Polaris Market Research. The report "Opioid Market Size, Share, Trends, Industry Analysis Report: By Class, Product, Release Type (Immediate-Release/Short-Acting Opioid and Extended-Release/Long-Acting Opioid), Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The opioid market growth is attributed to an increase in partnerships between companies. Collaborations between pharmaceutical firms, healthcare providers, and research institutions are facilitating the development of new formulations and improved delivery systems for opioid therapies. These alliances enable organizations to combine resources, leverage expertise, and expedite the research and development process, allowing for faster introduction of effective pain management solutions to the market. Additionally, strategic partnerships improve distribution networks and expand access to opioid medications, particularly in underserved areas. Companies join forces to address challenges related to opioid prescribing such as safety concerns and regulatory compliance; they are promoting a more holistic approach to pain management, ultimately strengthening the presence of opioids in the market.

The rising prevalence of traumatic injuries significantly drives opioid market demand due to the need for effective pain management. The US reports around 1.5 million traumatic brain injury cases annually, with many requiring hospitalization and long-term pain management. The CDC highlights that pain management is essential for recovery in these cases, increasing the demand for opioids. Additionally, heightened awareness of the long-term effects of TBIs emphasizes the necessity for comprehensive pain strategies, further leading to an expected rise in opioid prescriptions. Consequently, the opioid market size is poised for growth in the projected years.

The opioid market is expanding due to increased awareness and education about pain management. Both patients and healthcare providers are learning more about the different treatment options available. In the United States, nearly 50 million adults suffer from chronic pain. Updated medical guidelines are helping doctors feel more confident when prescribing opioids, ensuring they are used properly to manage pain. This growing understanding of pain treatment options is contributing to the rise in the use of opioids for managing chronic pain.

Opioid Market Report Highlights

By release type, the extended-release/long-acting opioid segment is anticipated to experience substantial growth at a significant CAGR in the global market during the forecast period. This growth is attributed to an increase in the prevalence of extended pain and traumatic injuries requiring long-acting opioids.

The pain management segment, by application, accounted for the largest revenue share of the market in 2024 due to the rising number of chronic and acute injuries.

In 2024, North America dominated the global opioid market share due to the increasing number hospitals, leading to the increase in prescription rate.

The opioid market in India is projected for substantial growth due to the increasing funding and foreign direct investment inflow.

A few global key market players are Aurobindo Pharma Limited; Assertio Therapeutics, Inc.; AbbVie Inc.; Actavis Plc.; Amneal Pharmaceuticals LLC; Boehringer Ingelheim International GmbH; Cadila Healthcare Limited; Fresenius Kabi; Mallinckrodt Pharmaceuticals; Endo International plc; Johnson & Johnson Corporation; Lupin Limited; Nesher Pharmaceuticals LLC; Purdue Pharma L.P.; Pfizer Inc.; Rhodes Pharmaceuticals L.P.; Sun Pharmaceutical Industries Limited; Trevena Inc.; Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the opioid market report on the basis of class, product, release type, application, and region:

By Class Outlook (Revenue - USD Billion, 2020-2034)

  • § Natural
  • § Semi-Synthetic
  • § Fully Synthetic

By Product Outlook (Revenue - USD Billion, 2020-2034)

  • § Codeine
  • § Fentanyl
  • § Oxycodone
  • § Methadone
  • § Morphine
  • § Hydrocodone
  • § Tramadol
  • § Propoxyphene
  • § Others

By Release Type Outlook (Revenue - USD Billion, 2020-2034)

  • § Immediate-Release/Short-Acting Opioid
  • § Extended-Release/Long-Acting Opioid
  • By Application (Revenue - USD Billion, 2020-2034)
  • § Pain Management
  • § Neuropathic
  • § Migraine
  • § Orthopedic and Musculoskeletal
  • § Arthritis
  • § Fibromyalgia
  • § Others
  • § Cancer Pain
  • § Brain
  • § Breast
  • § Colorectal
  • § Blood
  • § Skin
  • § Prostate
  • § Others
  • § Cough Treatment
  • § Analgesia
  • § Diarrhea Treatment
  • § De-addiction
  • § Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Opioid Market Insights

  • 4.1. Opioid Market - Market Snapshot
  • 4.2. Opioid Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Prevalence of Traumatic Injuries is Driving the Market Size
      • 4.2.1.2. Increasing Investment for Expansion of Medical Infrastructure Are Driving the Market Growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Stringent Government Regulation
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Opioid Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Opioid Market, by Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Opioid Market, by Class, 2020-2034 (USD billion)
  • 5.3. Natural
    • 5.3.1. Global Opioid Market, by Natural, by Region, 2020-2034 (USD billion)
  • 5.4. Semi-synthetic
    • 5.4.1. Global Opioid Market, by Semi-synthetic, by Region, 2020-2034 (USD billion)
  • 5.5. Fully synthetic
    • 5.5.1. Global Opioid Market, by Fully synthetic, by Region, 2020-2034 (USD billion)

6. Global Opioid Market, by Product

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Opioid Market, by Product, 2020-2034 (USD billion)
  • 6.3. Codeine
    • 6.3.1. Global Opioid Market, by Codeine, by Region, 2020-2034 (USD billion)
  • 6.4. Fentanyl
    • 6.4.1. Global Opioid Market, by Fentanyl, by Region, 2020-2034 (USD billion)
  • 6.5. Oxycodone
    • 6.5.1. Global Opioid Market, by Oxycodone, by Region, 2020-2034 (USD billion)
  • 6.6. Methadone
    • 6.6.1. Global Opioid Market, by Methadone, by Region, 2020-2034 (USD billion)
  • 6.7. Morphine
    • 6.7.1. Global Opioid Market, by Morphine, by Region, 2020-2034 (USD billion)
  • 6.8. Hydrocodone
    • 6.8.1. Global Opioid Market, by Hydrocodone, by Region, 2020-2034 (USD billion)
  • 6.9. Tramadol
    • 6.9.1. Global Opioid Market, by Tramadol, by Region, 2020-2034 (USD billion)
  • 6.10. Propoxyphene
    • 6.10.1. Global Opioid Market, by Propoxyphene, by Region, 2020-2034 (USD billion)
  • 6.11. Others
    • 6.11.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)

7. Global Opioid Market, by Release Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Opioid Market, by Release Type, 2020-2034 (USD billion)
  • 7.3. Immediate-release/Short-acting opioid
    • 7.3.1. Global Opioid Market, by Immediate-release/Short-acting opioid by Region, 2020-2034 (USD billion)
  • 7.4. Extended-release/Long-acting opioid
    • 7.4.1. Global Opioid Market, by Extended-release/Long-acting opioid, by Region, 2020-2034 (USD billion)

8. Global Opioid Market, by Application

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Opioid Market, by Application, 2020-2034 (USD billion)
  • 8.3. Pain Management
    • 8.3.1. Global Opioid Market, by Pain Management, by Region, 2020-2034 (USD billion)
    • 8.3.2. Neuropathic
      • 8.3.2.1. Global Opioid Market, by Neuropathic, by Region, 2020-2034 (USD billion)
    • 8.3.3. Migraine
      • 8.3.3.1. Global Opioid Market, by Migraine, by Region, 2020-2034 (USD billion)
    • 8.3.4. Orthopedic and Musculoskeletal
      • 8.3.4.1. Global Opioid Market, by Orthopedic and Musculoskeletal, by Region, 2020-2034 (USD billion)
    • 8.3.5. Arthritis
      • 8.3.5.1. Global Opioid Market, by Arthritis, by Region, 2020-2034 (USD billion)
    • 8.3.6. Fibromyalgia
      • 8.3.6.1. Global Opioid Market, by Fibromyalgia, by Region, 2020-2034 (USD billion)
    • 8.3.7. Others
      • 8.3.7.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)
  • 8.4. Cancer Pain
    • 8.4.1. Global Opioid Market, by Cancer Pain, by Region, 2020-2034 (USD billion)
    • 8.4.2. Brain
      • 8.4.2.1. Global Opioid Market, by Brain, by Region, 2020-2034 (USD billion)
    • 8.4.3. Breast
      • 8.4.3.1. Global Opioid Market, by Breast, by Region, 2020-2034 (USD billion)
    • 8.4.4. Colorectal
      • 8.4.4.1. Global Opioid Market, by Colorectal, by Region, 2020-2034 (USD billion)
    • 8.4.5. Blood
      • 8.4.5.1. Global Opioid Market, by Blood, by Region, 2020-2034 (USD billion)
    • 8.4.6. Skin
      • 8.4.6.1. Global Opioid Market, by Skin, by Region, 2020-2034 (USD billion)
    • 8.4.7. Prostate
      • 8.4.7.1. Global Opioid Market, by Prostate, by Region, 2020-2034 (USD billion)
    • 8.4.8. Others
      • 8.4.8.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)
  • 8.5. Cough treatment
    • 8.5.1. Global Opioid Market, by Cough treatment, by Region, 2020-2034 (USD billion)
  • 8.6. Analgesia
    • 8.6.1. Global Opioid Market, by Analgesia, by Region, 2020-2034 (USD billion)
  • 8.7. Diarrhea treatment
    • 8.7.1. Global Opioid Market, by Diarrhea treatment, by Region, 2020-2034 (USD billion)
  • 8.8. De-addiction
    • 8.8.1. Global Opioid Market, by De-addiction, by Region, 2020-2034 (USD billion)
  • 8.9. Others
    • 8.9.1. Global Opioid Market, by Others, by Region, 2020-2034 (USD billion)

9. Global Opioid Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Opioid Market Assessment, By Geography, 2020-2034 (USD billion)
  • 9.3. Opioid Market - North America
    • 9.3.1. North America: Opioid Market, by Class, 2020-2034 (USD billion)
    • 9.3.2. North America: Opioid Market, by Product, 2020-2034 (USD billion)
    • 9.3.3. North America: Opioid Market, by Release Type, 2020-2034 (USD billion)
    • 9.3.4. North America: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.3.5. Opioid Market - U.S.
      • 9.3.5.1. U.S.: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.3.5.2. U.S.: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.3.5.3. U.S.: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.3.5.4. U.S.: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.3.6. Opioid Market - Canada
      • 9.3.6.1. Canada: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.3.6.2. Canada: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.3.6.3. Canada: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.3.6.4. Canada: Opioid Market, by Application, 2020-2034 (USD billion)
  • 9.4. Opioid Market - Europe
    • 9.4.1. Europe: Opioid Market, by Class, 2020-2034 (USD billion)
    • 9.4.2. Europe: Opioid Market, by Product, 2020-2034 (USD billion)
    • 9.4.3. Europe: Opioid Market, by Release Type, 2020-2034 (USD billion)
    • 9.4.4. Europe: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.5. Opioid Market - UK
      • 9.4.5.1. UK: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.5.2. UK: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.5.3. UK: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.5.4. UK: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.6. Opioid Market - France
      • 9.4.6.1. France: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.6.2. France: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.6.3. France: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.6.4. France: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.7. Opioid Market - Germany
      • 9.4.7.1. Germany: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.7.2. Germany: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.7.3. Germany: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.7.4. Germany: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.8. Opioid Market - Italy
      • 9.4.8.1. Italy: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.8.2. Italy: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.8.3. Italy: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.8.4. Italy: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.9. Opioid Market - Spain
      • 9.4.9.1. Spain: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.9.2. Spain: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.9.3. Spain: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.9.4. Spain: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.10. Opioid Market - Netherlands
      • 9.4.10.1. Netherlands: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.10.2. Netherlands: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.10.3. Netherlands: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.10.4. Netherlands: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.11. Opioid Market - Russia
      • 9.4.11.1. Russia: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.11.2. Russia: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.11.3. Russia: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.11.4. Russia: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.4.12. Opioid Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.4.12.2. Rest of Europe: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.4.12.3. Rest of Europe: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.4.12.4. Rest of Europe: Opioid Market, by Application, 2020-2034 (USD billion)
  • 9.5. Opioid Market - Asia Pacific
    • 9.5.1. Asia Pacific: Opioid Market, by Class, 2020-2034 (USD billion)
    • 9.5.2. Asia Pacific: Opioid Market, by Product, 2020-2034 (USD billion)
    • 9.5.3. Asia Pacific: Opioid Market, by Release Type, 2020-2034 (USD billion)
    • 9.5.4. Asia Pacific: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.5. Opioid Market - China
      • 9.5.5.1. China: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.5.2. China: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.5.3. China: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.5.4. China: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.6. Opioid Market - India
      • 9.5.6.1. India: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.6.2. India: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.6.3. India: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.6.4. India: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.7. Opioid Market - Malaysia
      • 9.5.7.1. Malaysia: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.7.2. Malaysia: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.7.3. Malaysia: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.7.4. Malaysia: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.8. Opioid Market - Japan
      • 9.5.8.1. Japan: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.8.2. Japan: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.8.3. Japan: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.8.4. Japan: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.9. Opioid Market - Indonesia
      • 9.5.9.1. Indonesia: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.9.2. Indonesia: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.9.3. Indonesia: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.9.4. Indonesia: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.10. Opioid Market - South Korea
      • 9.5.10.1. South Korea: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.10.2. South Korea: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.10.3. South Korea: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.10.4. South Korea: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.11. Opioid Market - Australia
      • 9.5.11.1. Australia: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.11.2. Australia: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.11.3. Australia: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.11.4. Australia: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.5.12. Opioid Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.5.12.2. Rest of Asia Pacific: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.5.12.3. Rest of Asia Pacific: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.5.12.4. Rest of Asia Pacific: Opioid Market, by Application, 2020-2034 (USD billion)
  • 9.6. Opioid Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Opioid Market, by Class, 2020-2034 (USD billion)
    • 9.6.2. Middle East & Africa: Opioid Market, by Product, 2020-2034 (USD billion)
    • 9.6.3. Middle East & Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)
    • 9.6.4. Middle East & Africa: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.6.5. Opioid Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.6.5.2. Saudi Arabia: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.6.5.3. Saudi Arabia: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.6.5.4. Saudi Arabia: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.6.6. Opioid Market - UAE
      • 9.6.6.1. UAE: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.6.6.2. UAE: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.6.6.3. UAE: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.6.6.4. UAE: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.6.7. Opioid Market - Israel
      • 9.6.7.1. Israel: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.6.7.2. Israel: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.6.7.3. Israel: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.6.7.4. Israel: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.6.8. Opioid Market - South Africa
      • 9.6.8.1. South Africa: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.6.8.2. South Africa: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.6.8.3. South Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.6.8.4. South Africa: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.6.9. Opioid Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.6.9.2. Rest of Middle East & Africa: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.6.9.3. Rest of Middle East & Africa: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.6.9.4. Rest of Middle East & Africa: Opioid Market, by Application, 2020-2034 (USD billion)
  • 9.7. Opioid Market - Latin America
    • 9.7.1. Latin America: Opioid Market, by Class, 2020-2034 (USD billion)
    • 9.7.2. Latin America: Opioid Market, by Product, 2020-2034 (USD billion)
    • 9.7.3. Latin America: Opioid Market, by Release Type, 2020-2034 (USD billion)
    • 9.7.4. Latin America: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.7.5. Opioid Market - Mexico
      • 9.7.5.1. Mexico: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.7.5.2. Mexico: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.7.5.3. Mexico: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.7.5.4. Mexico: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.7.6. Opioid Market - Brazil
      • 9.7.6.1. Brazil: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.7.6.2. Brazil: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.7.6.3. Brazil: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.7.6.4. Brazil: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.7.7. Opioid Market - Argentina
      • 9.7.7.1. Argentina: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.7.7.2. Argentina: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.7.7.3. Argentina: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.7.7.4. Argentina: Opioid Market, by Application, 2020-2034 (USD billion)
    • 9.7.8. Opioid Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Opioid Market, by Class, 2020-2034 (USD billion)
      • 9.7.8.2. Rest of Latin America: Opioid Market, by Product, 2020-2034 (USD billion)
      • 9.7.8.3. Rest of Latin America: Opioid Market, by Release Type, 2020-2034 (USD billion)
      • 9.7.8.4. Rest of Latin America: Opioid Market, by Application, 2020-2034 (USD billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Aurobindo Pharma Limited
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Assertio Therapeutics, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. AbbVie Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Actavis Plc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Amneal Pharmaceuticals LLC
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Boehringer Ingelheim International GmbH
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Cadila Healthcare Limited
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Fresenius Kabi
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Mallinckrodt Pharmaceuticals
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Endo International plc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Johnson & Johnson Corporation
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Lupin Limited
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Nesher Pharmaceuticals LLC
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Purdue Pharma L.P.
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Pfizer Inc.
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Rhodes Pharmaceuticals L.P.
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Sun Pharmaceutical Industries Limited
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Trevena Inc.
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development
  • 11.19. Teva Pharmaceutical Industries Ltd.
    • 11.19.1. Company Overview
    • 11.19.2. Financial Performance
    • 11.19.3. Product Benchmarking
    • 11.19.4. Recent Development